This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence [AI]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is performing a prostate MRI. An MRI uses a magnetic field to take pictures of the body. The MRI images are examined by a radiologist. If a suspicious area is seen in the MRI, the radiologist assigns it a PIRADS score. This stands for Prostate Imaging Reporting and Data System. The PIRADS score is used to report how likely it is that a suspicious area in the prostate is cancer. The AI system has been developed also to be able to analyze prostate MRI images and detect suspicious areas in the prostate that may be cancer. The AI system’s ability to diagnose aggressive prostate cancer may be similar to detection performed by experienced radiologists using the standard PIRADS system of analyzing prostate MRI.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07162194.
Locations matching your search criteria
United States
California
Los Angeles
USC / Norris Comprehensive Cancer CenterStatus: Active
Contact: Andre Luis Abreu
Phone: 323-865-3000
PRIMARY OBJECTIVE:
I. To determine the non-inferiority of targeted biopsy according to Green Learning (GL) AI over Prostate Imaging Reporting & Data System (PIRADS).
SECONDARY OBJECTIVES:
I. To determine the clinically significant prostate cancer (CSPCa) detection rate on Deep Learning (DL) AI-targeted biopsy.
II. To determine the patient-level diagnostic performance of GL AI, DL AI and PIRADS for CSPCa detection.
III. To assess targeted biopsy core characteristics.
IV. To evaluate the predictors for patient-level CSPCa detection.
V. To assess the spatial correlation of CSPCa distribution on radical prostatectomy (RP) specimens and region of interest (ROI) generated by GL AI and PIRADS.
OUTLINE: Patients undergoing prostate biopsy per standard of care (SOC) are assigned to Group 1. Patients who underwent a prostate biopsy followed by a radical prostatectomy within 6 months, as well as patients only undergoing a radical prostatectomy are assigned to Group 2.
GROUP 1: Patients are randomized to 1 of 6 arms.
ARM I: Patients undergo MRI/transrectal ultrasound (TRUS) followed by a targeted prostate biopsy using PIRADS on study. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy based on GL AI predictions. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy based on DL AI predictions. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
ARM II: Patients undergo MRI/TRUS followed by a targeted prostate biopsy using PIRADS. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy based on DL AI predictions. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy based on GL AI predictions. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
ARM III: Patients undergo MRI/TRUS followed by a targeted prostate biopsy using GL AI predictions. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy using PIRADS. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy based on DL AI predictions. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
ARM IV: Patients undergo MRI/TRUS followed by a targeted prostate biopsy using GL AI predictions. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy based on DL AI predictions. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy using PIRADS. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
ARM V: Patients undergo MRI/TRUS followed by a targeted prostate biopsy using DL AI predictions. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy based on GL AI predictions. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy using PIRADS. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
ARM VI: Patients undergo MRI/TRUS followed by a targeted prostate biopsy using DL AI predictions. Patients then undergo a 2nd MRI/TRUS followed by a targeted prostate biopsy using PIRADS. Patients then undergo a 3rd MRI/TRUS followed by a targeted biopsy based on GL AI predictions. Finally, patients undergo up to 12 additional prostate biopsies per SOC.
GROUP 2: Patients have their removed prostate evaluated using a special mold on study. Prostate tissue is mapped and compared with the prostate cancer prediction on MRI generated by radiologists and AI reports.
After completion of study intervention, patients are followed up at 10 days.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUSC / Norris Comprehensive Cancer Center
Principal InvestigatorAndre Luis Abreu
